Cancer heterogeneity: Implications for targeted therapeutics

1] University College London Cancer Institute, London, UK [2] Department of Medicine, Royal Marsden Hospital, London UK.
British Journal of Cancer (Impact Factor: 4.84). 01/2013; 108(3). DOI: 10.1038/bjc.2012.581
Source: PubMed


Developments in genomic techniques have provided insight into the remarkable genetic complexity of malignant tumours. There is increasing evidence that solid tumours may comprise of subpopulations of cells with distinct genomic alterations within the same tumour, a phenomenon termed intra-tumour heterogeneity. Intra-tumour heterogeneity is likely to have implications for cancer therapeutics and biomarker discovery, particularly in the era of targeted treatment, and evidence for a relationship between intra-tumoural heterogeneity and clinical outcome is emerging. Our understanding of the processes that exacerbate intra-tumoural heterogeneity, both iatrogenic and tumour specific, is likely to increase with the development and more widespread implementation of advanced sequencing technologies, and adaptation of clinical trial design to include comprehensive tissue collection protocols. The current evidence for intra-tumour heterogeneity and its relevance to cancer therapeutics will be presented in this mini-review.British Journal of Cancer advance online publication, 8 January 2013; doi:10.1038/bjc.2012.581

45 Reads
  • Source
    • "The same applies when disruptive alterations hit on the same gene, e.g., pten's mutations and deletions in prostate cancer [25]. An immediate consequence of this state of affair is the dramatic heterogeneity and temporality of cancer, both at the inter-tumor and at the intra-tumor levels [26]. The former manifests as different patients with the same cancer type can display few common alterations. "
    [Show description] [Hide description]
    DESCRIPTION: The evolutionary nature of cancer relates directly to a renewed focus on the voluminous NGS (next generation sequencing) data, aiming at the identification of explanatory models of how the (epi)genomic events are choreographed in cancer initiation and development. However, despite the increasing availability of multiple additional -omics data, this quest has been frustrated by various theoretical and technical hurdles, mostly related to the dramatic heterogeneity and temporality of the disease. In this paper, we build on our recent works on selectivity relation among driver mutations in cancer progression and investigate their applicability to the modeling problem - both at the population and individual levels. On one hand, we devise an optimal, versatile and modular pipeline to extract ensemble-level progression models from cross sectional sequenced cancer genomes. The pipeline combines state-of-the-art techniques for sample stratification, driver selection, identification of fitness-equivalent exclusive alterations and progression model inference. We demonstrate this pipeline's ability to reproduce much of the current knowledge on colorectal cancer progression, as well as to suggest novel experimentally verifiable hypotheses. On the other hand, we prove that our framework can be applied, mutatis mutandis, in reconstructing the evolutionary history of cancer clones in single patients, as illustrated by an example with multiple biopsy data from clear cell renal carcinomas.
    • "In addition to regulating RNAPII CTD phosphorylation, CDK7 is a component of CDK-activating kinase (CAK), which is thought to phosphorylate and activate all CDKs, including cell-cycle CDKs (Schachter and Fisher, 2013). Indeed, CDK7 has been implicated in phosphorylating CDK1 and regulating mitosis (Larochelle et al., 2007), and THZ1 treatment has been shown to induce a G2/M arrest in neuroblastoma cells with MYCN amplification (Chipumuro et al., 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer that exhibits extremely high levels of genetic complexity and yet a relatively uniform transcriptional program. We postulate that TNBC might be highly dependent on uninterrupted transcription of a key set of genes within this gene expression program and might therefore be exceptionally sensitive to inhibitors of transcription. Utilizing kinase inhibitors and CRISPR/Cas9-mediated gene editing, we show here that triple-negative but not hormone receptor-positive breast cancer cells are exceptionally dependent on CDK7, a transcriptional cyclin-dependent kinase. TNBC cells are unique in their dependence on this transcriptional CDK and suffer apoptotic cell death upon CDK7 inhibition. An “Achilles cluster” of TNBC-specific genes is especially sensitive to CDK7 inhibition and frequently associated with super-enhancers. We conclude that CDK7 mediates transcriptional addiction to a vital cluster of genes in TNBC and CDK7 inhibition may be a useful therapy for this challenging cancer.
    Cell 09/2015; 163(1):174–186. DOI:10.1016/j.cell.2015.08.063 · 32.24 Impact Factor
  • Source
    • "Tumor cells are composed of heterogeneous subpopulations with distinct genotypes and phenotypes, which may harbor divergent biological behaviors [1]. Recently, there is accumulating evidence on the existence of a tumor subpopulation termed cancer stem cell (CSCs) with distinct characteristics resembling stem cells [2]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A rare subpopulation of cancer cells known as cancer stem cells (CSCs) have distinct characteristics resembling stem cells, including cell renewal capability, differentiation into multiple lineages, and endless prolifera-tion potential. Cumulating evidence has revealed that CSCs are responsible for tumorigenicity, invasion, metastasis, and therapeutic resistance. Despite continued investigation of CSCs, in vivo behavior of CSCs is not yet fully un-derstood. The in vivo imaging modalities of optical, nuclear, and magnetic resonance are currently being employed to investigate the complexity behind the CSCs behavior. Valuable information that were previously obscured by the limitations of in vitro techniques now are currently being revealed. These studies give us a more comprehensive insight about what happen to CSCs in vivo. This review will briefly discuss the recent findings on CSCs behavior as informed by in vivo imaging studies.
    American Journal of Nuclear Medicine and Molecular Imaging 01/2015; 5(1):14-26. · 3.25 Impact Factor
Show more